Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Ziagen;Kivexa;Trizivir (abacavir sulfate)-Important Safety Information from GlaxoSmithKline on genetic screening
Notice type:
3rd Party Publications
Date:
07/03/2008
Problem Or Issue:
Please find herewith an important safety communication from GlaxoSmithKline on screening for carriage of the HLA-B*5701 allele prior to the initiation of treatment with any abacavir sulfate-containing product
; these include Ziagen Tablets and Oral Solution, Kivexa Tablets and Trizivir Tablets.
« Back
Date Printed: 19/05/2024